PureTech Health (NASDAQ:PRTC) Trading Up 2% – What’s Next?

PureTech Health PLC Sponsored ADR (NASDAQ:PRTC)’s stock price was up 2% during mid-day trading on Wednesday . The stock traded as high as $17.84 and last traded at $17.42. Approximately 7,177 shares were traded during mid-day trading, a decline of 61% from the average daily volume of 18,326 shares. The stock had previously closed at $17.08.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut PureTech Health from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

PureTech Health Price Performance

The firm has a 50-day simple moving average of $16.84 and a 200-day simple moving average of $17.20.

PureTech Health (NASDAQ:PRTC) last posted its quarterly earnings data on Friday, April 10th. The company reported ($1.35) EPS for the quarter. The firm had revenue of $1.40 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in PureTech Health stock. Pentwater Capital Management LP lifted its stake in PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) by 50.0% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 75,000 shares of the company’s stock after buying an additional 25,000 shares during the quarter. Pentwater Capital Management LP owned about 0.31% of PureTech Health worth $1,388,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 0.04% of the company’s stock.

About PureTech Health

PureTech Health (NASDAQ: PRTC) is a clinical-stage biotherapeutics company focused on creating and developing first-in-class medicines across immunology, inflammation, oncology and neuroscience. The company operates through a model of incubating programs in-house and advancing selected assets into independent, value-creating entities. Its internal pipeline includes multiple clinical and preclinical candidates addressing fibrotic diseases, solid tumors and rare genetic disorders.

PureTech’s proprietary platform technologies span modalities such as monoclonal antibodies, small molecules and cell-based therapies.